Abstract
Acute myeloid leukemia (AML) is a genetically heterogeneous clonal malignancy characterized by recurrent gene mutations. Genomic heterogeneity, patients' individual variability, and recurrent gene mutations are the major obstacles among many factors that impact treatment efficacy of the AML patients. With the application of cost-and time-effective next-generation sequencing (NGS) technologies, an enormous diversity of genetic mutations has been identified. The recurrent gene mutations and their important roles in acute myeloid leukemia (AML) pathogenesis have been studied extensively. In this review, we summarize the recent development on the gene mutation in patients with AML.
Author supplied keywords
Cite
CITATION STYLE
Yu, J., Li, Y., Zhang, D., Wan, D., & Jiang, Z. (2020, March 27). Clinical implications of recurrent gene mutations in acute myeloid leukemia. Experimental Hematology and Oncology. BioMed Central Ltd. https://doi.org/10.1186/s40164-020-00161-7
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.